

## Results of Annual General Meeting

**Emyria Limited (ASX: EMD)** (Emyria or the Company), a data-backed clinical drug development and care delivery company, advises that its 2021 Annual General Meeting was held today, 3 November 2021. All resolutions put to the meeting were passed on a Poll. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company advises that details of the poll results and the proxies received in respect of each resolution are set out below:

### Poll Results

		For		Against		Abstain
Resolutions		Number	%	Number	%	Number
1	Adoption of Remuneration Report	38,719,990	98.7	505,000	1.3	253,869
2	Re-election of Dr Stewart Washer	110,208,208	100	0	0	156,250
3	Re-election of Dr Alistair Vickery	110,208,208	100	0	0	156,250
4	Approval of 10% Placement Facility	109,708,208	99.5	500,000	0.5	156,250

### Proxy Votes Received

Resolutions		For	Against	At Proxy Holders Discretion	Abstain
1	Adoption of Remuneration Report	31,401,739	505,000	192,400	253,869
2	Re-election of Dr Stewart Washer	102,889,957	0	192,400	156,250
3	Re-election of Dr Alistair Vickery	102,889,957	0	192,400	156,250
4	Approval of 10% Placement Facility	102,389,957	500,000	192,400	156,250



For further information:

**Dr. Michael Winlo**  
**Managing Director**  
**1300 436 363**

[mwinlo@emyria.com](mailto:mwinlo@emyria.com)

**Lexi O'Halloran**  
**Media/Investor Relations**  
**+ 61 (0) 404 577 076**

[lexi@janemorganmanagement.com.au](mailto:lexi@janemorganmanagement.com.au)

**Andrew Williams**  
**Media Relations**  
**+61 (0) 412 614 125**

[andrew@profilemedia.com.au](mailto:andrew@profilemedia.com.au)

---

### About Emyria ([www.emyria.com](http://www.emyria.com))

Emyria Limited is a data-backed clinical drug development and care delivery company focused on accelerating treatment development and improving patient care.

**Emyria's Treatments** target unmet needs and are focused on obtaining approval from major global regulators. Emyria's drug development programs are informed by insights generated from extensive analysis of **Emyria Data** - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria's independent clinical services (**Emerald Clinics** - [www.emeraldclinics.com.au](http://www.emeraldclinics.com.au))

**Emyria Data** provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs.

### Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.